Dr. Paul Hermonat, PhD.
CEO, Houston Gene Therapeutics

Dr. Paul Hermonat is the Founder and CEO of Houston Gene Therapeutics, INC. Dr, Hermonat is a founding researcher in the study of AAV-based molecular biology and gene therapeutics, conducting over 35-years of studies.

Paul Hermonat received a Ph.D. in Medical Microbiology from the University of Florida in 1984.  That same year he also received the University of Florida Medical Guild 1st Place in Research Award for his genetic analysis and first use of Adeno-Associated Virus (AAV) as a mammalian gene therapy vector.

Prior to founding Houston Gene Therapeutics (Texas), Dr. Hermonat served as the Endowed Chair of Cardiovascular Research at the University of Arkansas Medical Science, Head of Gene Therapy, and was a tenured professor in both Internal Medicine and OB/GYN (Little Rock).

Earlier in his career Dr. Hermonat conducted research at the National Institutes of Health (Bethesda, MD), was an independent researcher at The Johns Hopkins University (Baltimore, MD), and served as a Research Career Scientist at the Little Rock Veterans Administration Hospital.

Dr. Hermonat has been awarded multiple grants from organizations that include the Susan G. Komen Foundation, March of Dimes, Veterans Administration (Merit Review), and the National Institutes of Health (R01s). Additionally, Dr. Hermonat had the honor of being rewarded the rare R56 grant.

Dr. Hermonat is a pioneer in parvoviral science, specializing in AAV and its use in gene therapy. Dr. Hermonat is an active member of the scientific community with 156 total published scientific papers (138 of which are available on “Pubmed”).

Paul Hermonat Square.jpg

Dr. Paul Hermonat, PhD.

Experience in Therapeutic Gene Delivery Efficacy

For the record, here is the list of therapeutic genes evaluated for efficacy using AAV-based gene therapy by Dr. Paul Hermonat, PhD.

To our knowledge, our CEO's unparalleled experience is shown by the sheer number of genes tested for efficacy against the major diseases of inflammation and cancer, and then published on.

 

1) Initial testing of AAV efficiency (for completeness)

  • Neo (the 1st)

  • DHFR

  • Many other markers

2) Treating Cardio athero/inflam in mouse models (expensive and time consuming experiments)

  • hIL10

  • hFoxP3

  • hCGRP

  • hSMAD3

  • hPRDX6

  • hSTAT3

  • hIL10+hSTAT3

  • hAT2R

  • hTGFbeta1

  • hNetrin1

3) Destroying Cancer Cells using T cells and DC
from human peripheral blood, tested for generating highest killing CTL efficiency. This includes antigen gene delivery into DC and T cells.

  • hIL12

  • hIL7

  • hIFNγ

  • hGMCSF

  • hHer2/neu

  • hBA46

  • HPV16 E7

  • HPV16 E6

  • hPSMA

  • hPSA

  • HCV core, and truncated versions

  • HBV-C

  • HBV-S

  • HBV-X

  • hHM1.24

  • hCEA

  • hBA46

Join Dr. Paul Hermonat in the fight against the great diseases of our time.

For a limited time, Houston Gene Therapeutics, INC is accepting investor inquiries. For more information, contact us today.